URO-BCG-4 : Bladder Tumors Immunotherapy Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.

• Country None
• organs None
• Specialty None

PROSTACOX : Metastatic Prostate Chemotherapy Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

• Country France
• organs None
• Specialty None